clinical trial · NCT06768476
CART123 + Ruxolitinib in Relapsed/Refractory AML
Relapsed AMLRefractory AMLCART123 CellsRuxolitinib 10 MGRuxolitinib 5 MG
brief summary
Phase I, open-label study to assess the safety, feasibility, pharmacokinetics, and preliminary efficacy of CART123 cells given in combination with ruxolitinib in patients with relapsed or refractory acute myeloid leukemia (AML). All subjects will receive a single infusion of CART123 cells following ruxolitinib administration and lymphodepletion. Ruxolitinib dosing will begin at initiation of lymphodepleting chemotherapy (Day -6 ±1d) and continue for up to 14 days post CART123 administration.
started
Feb 28, 2025
primary completion
Mar 1, 2045
completion
Mar 1, 2045
last updated
Jan 16, 2026
official title
Phase I Trial of CART123 Cells Given in Combination With Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol